London, Jan 18, 2026, 19:15 GMT — Markets have closed for the day.
- AstraZeneca shares closed the week a bit up, as investors shrugged off a quiet weekend and focused on upcoming index flows and February earnings.
- The drugmaker warned of a challenging fourth quarter, citing the loss of last year’s milestone revenue and a seasonal rise in costs.
- Traders are eyeing the Nasdaq-100 reshuffle set for Jan. 20, along with AstraZeneca’s full-year earnings report due Feb. 10.
AstraZeneca shares ticked higher on Friday after the drugmaker highlighted several key drivers for its fourth-quarter performance ahead of the full-year results. The London-listed shares finished at 14,052 pence, gaining 0.2%, while U.S.-listed American Depositary Shares rose 0.4% to close at $94.39.
Markets are closed over the weekend, but the next move arrives fast—and it won’t be uniform across regions. U.S. exchanges remain shut on Monday for Martin Luther King Jr. Day, so London’s session will steer the direction before U.S. trading picks back up.
In a January “aide memoire” for analysts—a letter aimed at updating company consensus—AstraZeneca flagged a tougher year-on-year comparison for the fourth quarter. The prior-year quarter had more than $800 million in sales-based milestone revenue, which it doesn’t expect to see again. It also anticipates a sequential rise in R&D and SG&A (selling, general and administrative) costs compared to the third quarter. The company reiterated its 2025 guidance on a constant exchange rate basis, excluding currency fluctuations. AstraZeneca
Looking beyond the company’s schedule, Nasdaq announced Walmart will take AstraZeneca’s spot in the Nasdaq-100 and associated indexes before markets open on Jan. 20. This switch is likely to prompt index funds to rebalance, potentially intensifying price swings as the date approaches.
AstraZeneca’s investor calendar pins its full-year and fourth-quarter results for Feb. 10, with management roadshows lined up throughout February and first-quarter results slated for April 29. The February update should provide the next solid insight on 2026 growth, as the company transitions from late-stage readouts to fresh product launches.
Management remains confident about its long-term outlook. CFO Aradhana Sarin insists the $80 billion revenue goal for 2030 is “very much within reach.” Oncology head Dave Fredrickson noted a string of positive phase 3 trial results but acknowledged rising competition—including Johnson & Johnson’s Rybrevant/Lazcluze—in the lung cancer segment where AstraZeneca leads with Tagrisso. Fierce Pharma
Still, the stock faces a couple of persistent challenges. Pricing pressure in China, shifts in U.S. reimbursement, and how fast generic and biosimilar rivals emerge could all squeeze margins at the worst possible time—especially if the fourth-quarter results disappoint or 2026 spending spikes.
In London, AstraZeneca often tracks the broader pharma sector, especially when Washington weighs in on drug pricing or when rising rates push investors out of defensive stocks. On risk-off days, this context can be just as influential as the company’s own updates.
Monday’s London session marks the initial hurdle. The bigger moves are queued up just after: Tuesday’s Nasdaq-100 reshuffle and AstraZeneca’s results on Feb. 10.
